Thinly traded nano cap Artelo Biosciences (NASDAQ:ARTL) is up 60% premarket on robust volume in reaction to a $4.2M five-year NCI grant
that will fund the advancement of its fatty acid binding protein 5
(FABP5) inhibitor program. Specifically, the grant will support research
at Stony Brook University’s Institute of Chemical Biology and Drug
Discovery, in collaboration with Cold Spring Harbor Laboratory and
Artelo.
https://seekingalpha.com/news/3537263-nci-grant-boosts-artelo-bio-up-60-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.